

Adjunctive Corticosteroids for COVID-19: A Retrospective Cohort Study

Authors:

Ooi Say Tat MD MPH^{1,5}, Purnima Parthasarathy MBBS¹, Lin Yi MBBS MSc⁵,
Valliammai D/O Nallakaruppan MBBS MRCP MMed², Shereen Ng Jia Huey MBBS
MRCP MMed², Tan Teck Choon MBBS MRCP FAMS³, Low Serena MBBS MSc⁶,
Tang Terence MBBS MRCP⁴

Affiliation:

1. Division of Infectious Diseases, Department of General Medicine, Khoo Teck Puat hospital, Singapore
2. Division of General Medicine, Department of General Medicine, Khoo Teck Puat hospital, Singapore
3. Division of Rheumatology, Department of General Medicine, Khoo Teck Puat hospital, Singapore
4. Department of Geriatric Medicine, Khoo Teck Puat hospital, Singapore
5. Clinical Epidemiology Unit, Khoo Teck Puat hospital, Singapore
6. Clinical Research Unit, Khoo Teck Puat hospital, Singapore

Correspondence to:

Dr. Ooi Say Tat, Division of Infectious Diseases, Department of General Medicine,
Khoo Teck Puat hospital. 90 Yishun Central, Singapore 768828
Email: ooi.say.tat@ktph.com.sg

1 **ABSTRACT**

2

3 **Background:** Coronavirus disease 2019 (COVID-19) is associated with severe pneumonia,
4 respiratory failure and death. We aim to evaluate the efficacy of adjunctive corticosteroids in
5 the management of COVID-19.

6

7 **Methods:** This is a retrospective cohort study of hospitalized adults (≥ 18 years) who were
8 diagnosed with COVID-19 and were given treatment. Treatment included
9 hydroxychloroquine and lopinavir-ritonavir. Corticosteroids were included as adjunctive
10 therapy in mid-April, 2020. We compared composite outcomes of clinical progression and
11 invasive mechanical ventilation (MV) or death between group that received treatment only
12 (Group A) versus group that received adjunctive corticosteroids (Group B). Entropy
13 balancing was used to generate stabilized weight for covariates between treatment groups.
14 Unweighted Kaplan-Meier curves, weighted and adjusted Cox regression analysis were used
15 to estimate effect of adjunctive corticosteroids on composite outcomes. Subgroup analysis
16 was performed on those with pneumonia.

17

18 **Results:** Of 1046 patients with COVID-19, 57 received treatment alone (Group A) and 35
19 received adjunctive corticosteroids in addition to treatment (Group B). Median day of illness
20 at treatment initiation was 5 day. There were 44 patients with pneumonia; 68.9% of them
21 were not requiring supplemental oxygen at treatment initiation. Overall, 17 (18.5%) of 92
22 patients had clinical progression including 13 (22.8%) of 57 patients in Group A versus 4
23 (11.4%) of 35 patients in Group B ($p=0.172$). Unweighted Kaplan-Meier estimates showed
24 no significant difference in the proportion of patients who had clinical progression or invasive
25 MV or death between the 2 treatment groups. However in those with pneumonia, there were
26 lower proportions of patients in Group B with clinical progression (11.1%, 95% CI 0.0 - 22.2
27 versus 58.8%, 95% CI 27.3 - 76.7, log rank $p<0.001$); and invasive MV or death (11.3%,
28 95% CI 0.0 - 22.5 versus 41.2%, 95% CI 12.4. - 60.5, log rank $p=0.016$). In weighted and

29 adjusted cox regression analysis, patients in Group B were less likely to have clinical
30 progression, (adjusted HR [aHR] 0.08, 95% CI 0.01-0.99, p=0.049) but there was no
31 statistical significant difference in risk of requiring invasive MV or death (aHR 0.22, 95%CI
32 0.02 - 2.54, p=0.22). In subgroup with pneumonia, patients in Group B were significantly at
33 lower risk of clinical progression (aHR 0.15, 95% CI 0.06 - 0.39, p<0.001) and requiring
34 invasive MV compared to Group A (aHR 0.30, 0.10-0.87, p=0.029).

35

36 **Conclusions:** Use of adjunctive corticosteroids is associated with lower risk of clinical
37 progression and invasive MV or death, especially in those with pneumonia. Concurrent use
38 of antivirals and corticosteroids should be considered in the management of COVID-19
39 related pneumonia.

40

41 **Keywords:** COVID-19, corticosteroids, hydroxychloroquine

42

43 INTRODUCTION

44 Coronavirus disease 2019 (COVID-19) emerged in Wuhan city, China in December
45 2019 and has since evolved to a worldwide pandemic. Its clinical features range from
46 asymptomatic to severe pneumonia requiring invasive mechanical ventilation and
47 death.^{1,2,3}

48 Severe disease is typically marked by rapid clinical deterioration with features of
49 hyperinflammation.^{4,5}

50

51 Considering its pathophysiology, use of immunomodulatory agent and
52 corticosteroids have been proposed.⁶ Recent studies on use of tocilizumab and
53 dexamethasone have shown promising results in reducing mortality in severe

54 disease.^{7,8} However, treatment approach for early infection to prevent clinical
55 progression to severe disease remains unclear.

56

57 At our center, decision to treat and treatment selection have evolved over time. It
58 included interferon beta, lopinavir/ritonavir, hydroxychloroquine (HCQ).
59 Prednisolone and tocilizumab were included as part of the treatment for COVID-19
60 in mid-April 2020 when there was reported hyperinflammation related to COVID-19
61 and use of anti-inflammatory agent might improve clinical outcome.^{9,10,11,12} We aim
62 to evaluate the effect of adjunctive corticosteroids in the management of COVID-19.

63

64 METHODS

65 Study design and participants

66 This is a retrospective, observational cohort study of patients with COVID-19
67 admitted to our hospital from February 9, 2020 to May 31, 2020. Data was retrieved
68 from electronic medical records and included basic demographics, comorbidities,
69 laboratory investigations and medications administered.

70

71 We included adults (≥ 18 years) with COVID-19, confirmed by PCR on
72 nasopharyngeal swab who were admitted to our center and received treatment for
73 COVID-19. Those who were on supportive care only, on invasive mechanical
74 ventilation prior to treatment or those admissions not related to respiratory illness
75 were excluded.

76

77 This study was approved by Domain Specific Review Board.

78

79 **Treatment**

80 Decision to start treatment was at discretion of the treating physicians in consultation
81 with an Infectious Diseases physician. Treatment regimen included lopinavir/ritonavir
82 400/100 mg twice a day, hydroxychloroquine 400mg twice on day 1, followed by
83 200mg three times a day on days 2-5 and prednisolone. Dose of prednisolone varied
84 from 30mg once a day to 40mg twice a day at the physician's discretion depending
85 on severity of illness and patient's body weight. Corticosteroids use of 3 days or
86 more for any medical indications was considered as adjunctive corticosteroids.

87

88 Patients were classified into 2 groups, group that received usual treatment without
89 corticosteroids (Group A) and group that received adjunctive corticosteroids in
90 addition to usual treatment (Group B). Clinical conditions of the patients with COVID-
91 19 included at initiation of treatment were categorized into 3 stages: COVID-19
92 without pneumonia (Stage 1), COVID-19 related pneumonia not requiring
93 supplemental oxygen (Stage 2) and COVID-19 related pneumonia requiring
94 supplemental oxygen (Stage 3). Chest radiograph was the primary modality used in
95 the assessment for pneumonia in our cohort.

96

97 **Outcomes:**

98 Primary outcome was a composite of clinical progression or death. Clinical
99 progression is defined as progression to requirement of supplemental oxygen in
100 Stage 1 and 2 or progression to invasive mechanical ventilation in any stage
101 whichever is earlier. Secondary outcome was a composite of invasive mechanical
102 ventilation or death.

103

104 Subgroup analysis was performed on those with pneumonia (Stage 2 & 3)

105

106 **Statistical analysis:**

107 Categorical variables are shown as numbers and percentages while continuous
108 variables as median with interquartile range (IQR). Comparison of continuous and
109 categorical data between groups was done using Mann-Whitney U test and χ^2 test
110 or Fisher's exact test as appropriate.

111

112 Magnitude of changes in C-reactive protein (CRP) level following initiation of
113 treatment were calculated using available CRP values compared to baseline CRP
114 (delta CRP). Median values of delta CRP and daily maximum temperature following
115 initiation of treatment up to 14 days were plotted by treatment group for comparison.

116

117 Data was preprocessed with entropy balancing to achieve covariate balance
118 between the two treatment groups to reduce model dependence for the subsequent
119 estimation of treatment effects.¹³ Weight derived from maximum entropy reweighting
120 scheme was used to generate stabilized weight for each subject in the treatment
121 groups. Balanced covariate is defined by standardized mean difference of less than
122 0.1 and variance ratio between 0.5 - 2.0. Procedure of covariate balance was
123 performed separately for all eligible subjects and in subgroup with pneumonia.

124 Baseline covariates used to assess balanced weighting between treatment groups
125 were age, gender, body mass index (BMI), comorbidity, clinical stage, antibiotic use,
126 CRP, procalcitonin, lymphocyte count, neutrophils-lymphocyte ratio and creatinine.

127

128 Figure 2 displays the standardized mean difference of overall cohort subjects and
129 subgroup with pneumonia between the two treatment groups. Imbalanced covariates
130 between the two treatment groups were age, procalcitonin and creatinine. In
131 subgroup with pneumonia, age, procalcitonin, creatinine and neutrophil-lymphocyte
132 ratio were imbalanced (Table S1).

133

134 Missing data of covariates were mainly limited to CRP and procalcitonin (1.1%).
135 Multiple imputation was applied for missing data.

136

137 Kaplan Meier curves and cox regression analysis were used to compare time to
138 composite outcomes between 2 treatment groups. Patients without primary end-point
139 event were censored on date of discharge. Proportions of patients with composite
140 outcomes between 2 treatment groups were compared using unweighted Kaplan-
141 Meier estimates. We used weighted Cox proportional-hazards regression models
142 with adjustment for imbalanced covariates to estimate effect of adjunctive
143 corticosteroids on composite outcomes. The effect estimate is shown using hazard
144 ratio (HR) with 95% confidence interval (95% CI).

145

146 We considered two-sided p value test of less than 0.05 as statistically significant.
147 Comparison of baseline characteristics by treatment group, patterns of fever and
148 CRP changes following treatment was performed using STATA version 15 (STATA
149 Corp., Texas, USA). Multiple imputation, entropy balancing with covariate balance
150 assessment and Cox regression analyses were performed using R Statistical
151 Software (Foundation for Statistical Computing, Vienna, Austria) and related R
152 packages (MICE, WeightIt, ebal and Cobalt).^{14,15}

153

154 **RESULTS**

155 Between February 9, 2020 and May 31, 2020, there were 1046 patients with covid-

156 19 admitted to our hospital. Of these, 94 (9.0%) patients received treatment. Two

157 patients were excluded as treatment was started following invasive mechanical

158 ventilation. In total, 57 patients received treatment without corticosteroids (Group A)

159 and 35 patients received adjunctive prednisolone to treatment (Group B). (Figure 1)

160

161 Median number of days of illness at the start of treatment was 4 days and 5 days in

162 Group A and B respectively. Duration of HCQ used was 7 days (IQR 5-7) in Group A

163 and 5 days (IQR 5-7) in Group B.

164 Prednisolone use was 5 days (IQR 3-7).

165

166 There were 44 patients in the cohort who had pneumonia. Of these, 68.9% of them

167 were not requiring supplemental oxygen at treatment initiation. Between the 2

168 groups, there were higher proportions of patients in Group B who had pneumonia

169 and requiring supplemental oxygen, use of antibiotics and higher CRP level at

170 initiation of treatment (Table 1). Eight subjects received tocilizumab in our cohort. All

171 were given post mechanical ventilation except 2 cases (one in each treatment

172 group).

173

174 Following treatment initiation, body temperature of patients trended down in similar

175 pattern between the 2 treatment groups. CRP in Group B trended down. However, in

176 Group A, it trended up at around 5-8 days following treatment before declining

177 (Figure 3).

178

179 Overall, 17 (18.5%) of 92 patients had clinical progression including 13 (22.8%) of 57
180 patients in Group A versus 4 (11.4%) of 35 patients in Group B ($p=0.172$) (Table S2
181 in supplementary material).

182 There were 11 patients required invasive mechanical ventilation; 7 (12.2%) patients
183 in Group A and 4 (11.4%) patients in Group B. One death occurred in Group A
184 following invasive mechanical ventilation and none in Group B.

185

186 Unweighted Kaplan-Meier estimates showed no significant difference in the
187 proportion of patients who had clinical progression or invasive mechanical ventilation
188 between the 2 treatment groups (Figure 4). At day 12 after treatment initiation, the
189 proportion of patients with clinical progression was 23.3% (95% CI 11.3 - 33.7) in
190 Group A versus 11.4% (95% CI 0.2 - 21.4) in Group B (log rank $p=0.16$); 12.3%
191 (95% CI 3.3. - 20.4) of patients in Group A required invasive mechanical ventilation
192 versus 12.2% (95% CI 0.2 - 22.7) of patients in Group B (log rank $p=0.85$). However,
193 in subgroup analysis of those with pneumonia, there was beneficial effect of
194 adjunctive prednisolone compared to treatment alone. At day 12 after treatment
195 initiation, the proportion of patients with clinical progression was 58.8% (95% CI 27.3
196 - 76.7) in Group A versus 11.1% (95% CI 0.0 - 22.2) in Group B (log rank $p<0.001$);
197 41.2% (95% CI 12.4. - 60.5) of patients in Group A required invasive mechanical
198 ventilation versus 11.3% (95% CI 0.0 - 22.5) of patients in Group B (log rank
199 $p=0.016$).

200

201 In unadjusted cox regression, there was no significant difference in risk of clinical
202 progression between the two treatment groups (Table 3). In weighted and adjusted

203 cox regression analysis, patients in Group B were less likely to have composite
204 outcome of clinical progression compared to Group A, (adjusted HR [aHR] 0.08, 95%
205 CI 0.01-0.99, p=0.049) but there was no statistical significant difference in risk of
206 requiring invasive mechanical ventilation or death (aHR 0.22, 95%CI 0.02 - 2.54,
207 p=0.22) . In subgroup analysis of those with pneumonia, patients in Group B were
208 significantly at lower risk of clinical progression (aHR 0.15, 95% CI 0.06 - 0.39,
209 p<0.001) and requiring invasive mechanical ventilation compared to Group A (aHR
210 0.30, 0.10-0.87, p=0.029).

211

212 **DISCUSSION**

213 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
214 characterized by high viral replication during the initial phase of illness and a robust
215 hyper immune response leading to morbidity and mortality.^{9,10,16} Our study provides
216 important insights into the management of early COVID-19-related pneumonia,
217 particularly highlighting the need to address both the viral replication and the
218 inflammatory response in the early stages of infection.

219

220 Our cohort of patients either received antiviral alone (mostly HCQ) or were treated
221 with a combination of HCQ and corticosteroids (Prednisolone) during the early phase
222 of illness. The use of adjunctive prednisolone along with HCQ was associated with a
223 significantly lowered risk of clinical disease progression, especially in those with
224 pneumonia. 68.9% of patients with pneumonia in our cohort were not on
225 supplemental oxygen at initiation of treatment. Early use of prednisolone in our
226 patients with COVID-19 pneumonia and not on supplemental oxygen, had a 70%
227 lower risk of progressing to invasive mechanical ventilation or death compared to

228 non-steroid group-(HR 0.30, 95% CI 0.10 - 0.87). The duration of prednisolone use in
229 our cohort was short, with a median of 5 days. The dose of prednisolone varied
230 between 0.5-1.0 mg/kg/day.

231

232 Emerging data have shown benefits of anti-inflammatory agents in the management
233 of severe COVID-19 pneumonia, especially with the use of tocilizumab and
234 corticosteroids.^{7,8} The RECOVERY trial involving the use of dexamethasone in
235 hospitalized patients with COVID-19 in UK showed a 20%-40% reduction in mortality
236 in those with pneumonia requiring oxygen and invasive mechanical ventilation.

237 However, there was a trend towards increased mortality when corticosteroids were
238 used in patients not receiving respiratory support at randomization.⁸ This seems to
239 correspond to use of corticosteroids in early pneumonia. Earlier observations of
240 adverse outcomes with corticosteroids use in SARS and Middle East respiratory
241 syndrome (MERS-CoV) infections may explain the undesired consequences of
242 corticosteroids in early phase of COVID-19 pneumonia at which virus replication is
243 active.¹⁷

244

245 HCQ has been shown to effectively inhibit SARS-CoV-2 infection in vitro.¹⁸ Despite
246 its in-vitro activity, clinical efficacy of HCQ has largely been reported as ineffective.
247 The RECOVERY trial reported an increased risk of invasive mechanical ventilation
248 or death with use of HCQ compared to supportive care.¹⁹ We found that the group
249 on treatment with antivirals without adjunctive corticosteroids in our cohort had a
250 more protracted course with a higher inflammatory response. Their CRP tended to
251 higher level at day 5-8 post treatment despite a similar fever response in both
252 groups. Perhaps this is a paradoxical inflammatory reaction due to treatment. We

253 might draw simile to post-treatment inflammatory response in *pneumocystis jiroveci*
254 pneumonia, where early adjunctive corticosteroids could decrease risk of respiratory
255 failure.²⁰

256

257 The use of prednisolone during early pneumonia in our study had a significantly
258 better outcome which may be due to the concurrent administration of antiviral agents
259 such as HCQ or lopinavir/ritonavir. A similar observation could be from a
260 retrospective study that showed significant lower risk of invasive mechanical
261 ventilation or death with the use of tocilizumab to standard care that included HCQ
262 and lopinavir/ritonavir in the first week of COVID-19 pneumonia.⁷

263

264 The prominent protective effect of adjunctive prednisolone observed in our cohort
265 with early pneumonia and the varying effect of dexamethasone on different days of
266 illness of COVID-19 in the RECOVERY trial suggest the need for different treatment
267 strategies at different clinical stages of COVID-19 infection. Our results support the
268 hypothesis that control of both viral replication and inflammatory response is
269 important in treatment of early COVID-19 pneumonia.⁵

270

271 Our study has several limitations. Without a placebo arm, we are unable to conclude
272 if the protective effect observed in our study was directly due to corticosteroids alone
273 or in combination with a treatment agent, mostly HCQ. Non-randomized treatment
274 selection and small sample size could have biased estimates and limit our subgroup
275 analysis. The estimates in weighted regression are dependent on balancing of
276 covariates and confounders.

277

278 Despite non-parametric method of covariate balancing, there were some imbalances
279 that required further covariate adjustment in regression models. Our estimates could
280 subject to possible model misspecification and are based on assumption that all
281 confounders are controlled. In a conservative view, estimates in unadjusted cox
282 regression did not show an increased risk of composite outcomes despite seemingly
283 more severe disease in group that received adjunctive corticosteroids. Having said
284 that, risk of secondary infection and other adverse outcomes associated with
285 corticosteroids were not evaluated.

286

287 Our analysis could not account for change in clinical practice and experience gained
288 in managing COVID-19 over time that might affect better outcome in the later stage.
289 However, it is unlikely to account for lower risk of clinical progression of requiring
290 oxygen in those with pneumonia on adjunctive corticosteroids.

291

292 Lastly, younger population in our cohort and single center design may limit
293 generalizability of these results to other populations.

294

295 In summary, our study shows that the use of adjunctive corticosteroids was
296 associated with lower risk of clinical progression and invasive MV or death,
297 especially in those with pneumonia. Patients in early phase of COVID-19 pneumonia
298 may benefit from adjunctive corticosteroid therapy. Further prospective studies are
299 required to evaluate the clinical efficacy of a combination treatment with antivirals
300 and anti-inflammatory agents in early COVID 19 pneumonia.

301

302

303 REFERENCES

304

305 1. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from
306 an asymptomatic contact in Germany. *N Engl J Med* 2020;382:970-971.

307

308 2. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
309 China. *N Engl J Med* 2020;382:1708-20.

310

311 3. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With
312 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.

313

314 4. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. *J Clin Invest.*
315 2020;130(5):2202-2205.

316

317 5. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A
318 clinical-therapeutic staging proposal. *J Heart Lung Transplant.* 2020;39(5):405-407.

319

320 6. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm
321 syndromes and immunosuppression. *Lancet.* 2020;395(10229):1033-1034.

322

323 7. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe
324 COVID-19: a retrospective cohort study. *Lancet Rheumatol* 2020; published online
325 June 24. [https://doi.org/10.1016/S2665-9913\(20\)30173-9](https://doi.org/10.1016/S2665-9913(20)30173-9)

326

327 8. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with
328 Covid-19 — preliminary report. *N Engl J Med.* 2020. DOI: 10.1056/NEJMoa2021436.

329

- 330 9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
331 coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497–506.
- 332
- 333 10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
334 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*.
335 2020;395(10229):1054-1062.
- 336
- 337 11. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress
338 syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan,
339 China. *JAMA Intern Med* 2020;180(7):1–11.
- 340
- 341 12. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single
342 center experience. *J Med Virol*. 2020;92(7):814-818.
- 343
- 344 13. Hainmueller J. Entropy Balancing for Causal Effects: A Multivariate Reweighting
345 Method to Produce Balanced Samples in Observational Studies. *Political Analysis*.
346 2012;20(1):25 - 46
- 347 14. van Buuren S, Groothuis-Oudshoorn K (2011). mice: Multivariate Imputation by
348 Chained Equations in R. *Journal of Statistical Software*, 45(3),1-67.
- 349
- 350 15. Greifer, N. cobalt: Covariate Balance Tables and Plots. R package version 4.2.2
351 (2020)
- 352
- 353 16. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior
354 oropharyngeal saliva samples and serum antibody responses during infection by
355 SARS-CoV-2: an observational cohort study. *Lancet Infect Dis*. 2020;20(5):565-574.
- 356

357 17. Russell CD, Millar JE, Baillie, JK. Clinical evidence does not support corticosteroid
358 treatment for 2019-nCoV lung injury. *Lancet*. 2020;395(10223):473-475.

359

360

361 18. Liu, J., Cao, R., Xu, M. et al. Hydroxychloroquine, a less toxic derivative of
362 chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov*.
363 2020;6:16.

364

365 19. Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized
366 Patients with COVID-19: Preliminary results from a multi-centre, randomized,
367 controlled trial. medRxiv 2020. Available at:

368 <https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1>

369

370 20. Gagnon S, Boota AM , Fischl MA , e t al. Corticosteroids as adjunctive therapy for
371 severe *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome:
372 a double-blind, placebo-controlled trial. *N Eng J Med* 1990; 323:1444-1450

373

374

375

376

377

378

379

380

381

382

383 **Table and figures**

384
385
386

387 Figure 1: Overview of patients included in the study cohort

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

434

435

436

437

438

439

440

441


442

443

444

445

446



447

Table 1: Baseline characteristics of overall cohort by treatment group

	Group A N=57 (%)	Group B N=35 (%)	P-value
Age (year)	50 (36-58)	48 (41-57)	0.94
Female	12(21%)	4(11%)	0.24
Ethnicity			0.10
Chinese	12 (21%)	14 (40%)	
Malay	10 (18%)	1(3%)	
Indian	17(30%)	8(23%)	
Others	18 (31%)	12 (34%)	
Body mass index (kg/m ²)	25.5 (23.4-28.4)	25.6 (21.7-26.7)	0.40
Comorbidity present			
Diabetes mellitus	14 (25%)	14 (40%)	0.12
Hypertension	16 (28%)	6 (17%)	0.23
Hyperlipidaemia	7 (12%)	3 (9%)	0.58
Renal diseases	10 (18%)	5 (14%)	0.68
Cardiac diseases	3 (5%)	2 (6%)	0.93
Neurological diseases	0 (0%)	1 (3%)	0.20
Rheumatologic diseases	2 (4%)	1 (3%)	0.86
Respiratory diseases	1 (2%)	1(3%)	0.72
Day of Illness*	4 (2, 6)	5 (4, 9)	0.064
Clinical Stage upon treatment			<0.001
Stage 1	40 (70%)	8 (23%)	
Stage 2	13 (23%)	18 (51%)	
Stage 3	4 (7%)	9 (26%)	
Max Temperature (°C)**	38.5 (38.1-39.1)	38.8 (38.4-39.3)	0.06
Use of antibiotics before treatment	14 (25%)	20 (57%)	0.002
Use of inotropes	2(4%)	0 (0%)	0.26
Use of tocilizumab	3(5%)	5 (14%)	0.14
C-reactive protein (mg/L)	12.7 (6.2-33.9)	60.7 (37.9-109.3)	<0.001
Procalcitonin (ng/mL)	0.10 (0.06- 0.15)	0.13 (0.08-0.27)	0.039
White blood cells (x10 ⁹ /L)	5.5 (4.6- 6.9)	6.3 (4.1, 8.9)	0.27
Lymphocytes (x10 ⁹ /L)	1.2 (0.9-1.6)	1.2 (0.9-1.6)	0.95
Neutrophils (x10 ⁹ /L)	3.7 (2.6- 4.8)	4.7(2.9-6.4)	0.05
Monocytes (x10 ⁹ /L)	0.51 (0.36-0.83)	0.37 (0.27-0.51)	0.004
Creatinine (umol/L)	84 (73-94)	74 (67-87)	0.06
Bicarbonate (mmol/L)	24 (23-26)	24 (23-25)	0.54
Aspartate aminotransferase (U/L)	30 (21-37)	33 (23-44)	0.24
Alanine aminotransferase (U/L)	28 (22-37)	32 (20-41)	0.63

448

Data are median (IQR) or n(%) unless otherwise stated. P values were calculated using Mann-Whitney U test and χ^2 test or Fisher's exact test as appropriate.

449

*Day of illness represent the number of day of illness by symptoms on the day of treatment initiation.

450

**Max temperature is the highest recorded body temperature on the day of treatment initiation.

451

452

453

454

455

456

457

458

459


460

461

462

463

464 Figure 2. Adjusted and unadjusted covariate balance in overall cohort(a) and in subgroup
465 with pneumonia(b) between two treatment groups.
466
467
468



469
470 a.
471
472

B.

473 Temperature is the highest recorded body temperature on the day of treatment initiation. bmi, body mass index;
474 wbc, white blood cells; NLR, neutrophil-lymphocyte ratio; CRP, C-reactive protein.
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504


505 Table 3. Unadjusted and adjusted relative hazards of clinical progression and Invasive
506 mechanical ventilation
507

	N	Unadjusted analysis HR (95% CI)	p value	Adjusted analysis HR (95% CI)	p value
Clinical Progression					
Overall	92	0.46(0.15 – 1.40)	0.169	0.08 (0.01 – 0.99)	0.049
Pneumonia	44	0.13(0.04 – 0.48)	0.002	0.15 (0.06 – 0.39)	<0.001
Invasive Mechanical Ventilation					
Overall	92	0.88 (0.26 – 3.02)	0.844	0.22 (0.02 – 2.54)	0.22
Pneumonia	44	0.22 (0.06 – 0.85)	0.028	0.30 (0.10 – 0.87)	0.029


508
509 N, number; HR, hazard ratio; CI, confidence interval.
510 For adjusted HR in overall group, age, C-reactive protein, procalcitonin were adjusted using weighted Cox
511 regression analysis.
512 For adjusted HR in pneumonia, age, C-reactive protein, procalcitonin and neutrophil-lymphocyte ratio were
513 adjusted using weighted Cox regression analysis.
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550

551 Figure 3: Trends of fever and changes of C-reactive protein level by treatment groups.
552
553

(a)




554
555 (b)



556
557
558
559 Note: delta C-reactive protein (CRP) is the changes in CRP level following initiation of treatment were calculated
560 compared to baseline CRP level at initiation of treatment
561

562
563
564
565
566
567
568
569

Figure 4. Kaplan-Meier estimates of the cumulative probability of clinical progression and mechanical ventilation or death by treatment group.



570
571
572
573
574

575
576
577
578
579
580
581
582
583
584
585
586
587
588
589

590 Supplementary Material
591

592 Table S1a. Covariate balance of the overall cohort between two treatment groups
593

Covariate	Type	Unadjusted difference*	Unadjusted Variance Ratio	Adjusted difference*	Adjusted Variance Ratio
Age	Continuous	0.0668	0.8349	0.0005	0.351
Female	Binary	-0.0926	NA	0.0376	NA
BMI	Continuous	-0.2848	0.6576	-0.0005	0.9822
Comorbidity	Binary	0.1345	NA	-0.0001	NA
Stage_1	Binary	-0.4611	NA	-0.0007	NA
Stage 2	Binary	0.2901	NA	0.0005	NA
Stage 3	Binary	0.1709	NA	0.0002	NA
Temperature**	Continuous	0.4306	0.8152	0.0003	0.6452
White cells	Continuous	0.2761	1.7111	-0.0565	1.8464
Lymphocytes	Continuous	0.1061	1.5234	-0.0005	1.8224
Neutrophils-lymphocyte ratio	Continuous	0.1533	1.1089	0.0004	1.4704
Creatinine	Continuous	-0.3333	0.8675	-0.5859	0.6754
C-reactive protein	Continuous	0.7969	2.304	0.0007	0.5673
Procalcitonin	Continuous	0.4382	8.9343	0.0003	2.8179
Antibiotic use	Binary	0.3128	NA	0.0003	NA

594
595 Table S1b. Covariate balance of subgroup with pneumonia between two treatment groups
596
597

598 *Standardized mean difference

599 **Highest temperature recorded on the day of treatment initiation

600 NA is non-applicable

601
602

Covariate	Type	Unadjusted difference*	Unadjusted Variance Ratio	Adjusted difference*	Adjusted Variance Ratio
Age	Continuous	-0.7017	1.6742	-0.0149	2.0342
Female	Binary	-0.2593	NA	-0.0043	NA
BMI	Continuous	-0.7953	0.6944	-0.0018	0.9756
Comorbidity	Binary	-0.2037	NA	0.002	NA
Stage_1	Binary	-0.0556	NA	-0.0031	NA
Stage 2	Binary	0.0926	NA	-0.0012	NA
Stage 3	Binary	-0.037	NA	0.0043	NA
Temperature**	Continuous	0.5164	0.866	0.013	0.719
WBC	Continuous	0.2812	1.1032	0.0097	0.574
Lymphocytes	Continuous	0.3371	1.8044	0.0143	1.8283
Neutrophils-lymphocyte ratio	Continuous	-0.0416	0.3842	-0.0019	0.2974
Creatinine	Continuous	-0.655	0.3425	-0.7311	0.2618
CRP	Continuous	0.5912	2.5667	0.475	1.6594
Procalcitonin	Continuous	0.2891	5.1193	0.1091	4.1444
Antibiotic use	Binary	-0.0741	NA	0.0025	NA

603
604
605
606
607
608
609
610

611 Table S2. Composite outcomes by clinical stages and treatment groups
612

Composite of Clinical progression	Stage 1		Stage 2		Stage 3	
	Group A (n=40)	Group B (n=8)	Group A (n=13)	Group B (n=18)	Group A (n=4)	Group B (n=9)
Supplemental oxygen only	3 (7.5%)	1 (12.5%)	7 (53.8%)	1 (5.6%)	NA	NA
Invasive mechanical ventilation	0 (0%)	1 (12.5%)	4 (30.8%)	1 (5.6%)	3 (75%)	2 (22.2%)

613
614 Stage 1, no pneumonia; Stage 2, pneumonia with no supplemental oxygen; Stage 3, pneumonia on
615 supplemental oxygen
616